Aspire-Lakewood Holdings, Inc.
ASBP Nasdaq Pharmaceutical Preparations Financials FY2022โFY2025
Last close ยท Oct 23, 2026
$8.80
1.1%What Aspire-Lakewood Holdings, Inc. does
No business description yet.
- Legal name
- Aspire-Lakewood Holdings, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 30, 2026
- Accession ยท CIK
- 0001493152-26-013682
0001847345
Revenue and margins
Aspire-Lakewood Holdings, Inc. had $0.0M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Aspire-Lakewood Holdings, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 116.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Aspire-Lakewood Holdings, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.5M | $0.0M | $0.0M | $1.0M |
| Interest coverage | โ | โ | โ12.4x | โ2.3x |
| Current ratio | 3.6x | 0.2x | 0.1x | 0.2x |
| Quick ratio | 3.6x | 0.2x | 0.1x | 0.1x |
| Total assets | $300M | $20.0M | $0.1M | $1.3M |
| Total liabilities | $11.1M | $0.4M | $1.7M | $7.7M |
| Shareholders' equity | โ$9.9M | โ$0.5M | โ$1.5M | โ$6.4M |
| Net debt (โ = net cash) | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | โ / 5 | โ / 6 |
| Accruals ratio | 1.6% | 3.2% | โ10.4% | โ2,678.7% |
| Altman Z'' | โ | โ | โ185.38 | โ199.09 |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | โ | โ | โ | $0.0M |
| Gross profit | โ | โ | โ | โ$0.0M |
| Research and development | โ | โ | $0.1M | $0.9M |
| Operating income | โ | โ | โ$1.2M | โ$19.4M |
| Interest expense | โ | $0.0M | $0.1M | $8.5M |
| Pretax income | โ | โ | โ$1.3M | โ$24.5M |
| Income tax | โ | โ | $0.0M | โ |
| Net income | $3.3M | $4.5M | โ$1.3M | โ$24.5M |
| Diluted EPS | โ | โ | โ$1.90 | โ$16.38 |
| Diluted shares | โ | โ | 0.00B | 0.00B |
| Cash flow | ||||
| Cash from operations | โ$1.4M | โ$0.7M | โ$0.3M | โ$4.9M |
| Stock-based compensation | โ | โ | $0.0M | $14.1M |
| Share buybacks | โ | $285M | $13.8M | โ |
| Dividends and buybacks | โ | $285M | $13.8M | โ |
| Balance sheet | ||||
| Cash and short-term investments | $0.5M | $0.0M | $0.0M | $1.0M |
| Current assets | $1.1M | $0.1M | $0.1M | $1.3M |
| Current liabilities | $0.3M | $0.4M | $1.7M | $7.6M |
| Inventory | โ | โ | โ | $0.3M |
| Total assets | $300M | $20.0M | $0.1M | $1.3M |
| Total liabilities | $11.1M | $0.4M | $1.7M | $7.7M |
| Shareholders' equity | โ$9.9M | โ$0.5M | โ$1.5M | โ$6.4M |
| Margins | ||||
| Gross margin | โ | โ | โ | โ1.6% |
| Operating margin | โ | โ | โ | โ312,117.7% |
| Net margin | โ | โ | โ | โ394,851.6% |
| Returns | ||||
| Return on capital employed | โ | โ | 78.6% | 308.1% |
| Return on assets | 1.1% | 2.8% | โ13.0% | โ3,353.1% |
| Growth | ||||
| Net income growth | โ | 33.6% | โ129.3% | โ |
| Share count change | โ | โ | โ | 116.7% |
| Financial health | ||||
| Interest coverage | โ | โ | โ12.4x | โ2.3x |
| Current ratio | 3.6x | 0.2x | 0.1x | 0.2x |
| Quick ratio | 3.6x | 0.2x | 0.1x | 0.1x |
| Capital allocation | ||||
| Stock comp / revenue | โ | โ | โ | 227,924.2% |
| Quality scores | ||||
| Altman Z'' | โ | โ | โ185.4 | โ199.1 |
| Accruals ratio | 1.6% | 3.2% | โ10.4% | โ2,678.7% |
Source: SEC EDGAR XBRL filings (CIK 0001847345). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
